4D Molecular Therapeutics...

2.89
-0.39 (-11.89%)
At close: Apr 03, 2025, 3:59 PM
3.02
4.50%
After-hours: Apr 03, 2025, 06:39 PM EDT

Company Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.

It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.

The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.

Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF.

The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.

It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology.

The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.

Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF.

The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc. logo
Country United States
IPO Date Dec 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 227
CEO Dr. David H. Kirn M.D.

Contact Details

Address:
5858 Horton Street
EmeryVille, California
United States
Website https://www.4dmoleculartherapeutics.com

Stock Details

Ticker Symbol FDMT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001650648
CUSIP Number 35104E100
ISIN Number US35104E1001
Employer ID 47-3506994
SIC Code 2836

Key Executives

Name Position
Dr. David H. Kirn M.D. Co-Founder, Chief Executive Officer & Director
Dr. Fariborz Kamal Ph.D. President & Chief Operating Officer
Dr. Scott P. Bizily J.D., Ph.D. Chief Legal Officer & Corporate Secretary
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D. Senior Vice President & Therapeutic Area Head of Pulmonology
Dr. An Song Ph.D. Chief Development Officer
Dr. John F. Milligan Ph.D. Executive Chairman
Dr. Noriyuki Kasahara M.D., Ph.D. Chief Scientific Officer
Dr. Robert Y. Kim M.B.A., M.D. Chief Medical Officer
Theresa Janke Co-Founder & Chief of Staff
Uneek Mehra Chief Financial & Business Officer

Latest SEC Filings

Date Type Title
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing
Feb 28, 2025 POS AM Filing
Feb 28, 2025 S-8 Filing
Feb 28, 2025 10-K Annual Report
Feb 28, 2025 8-K Current Report
Feb 28, 2025 POSASR Filing